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Abstract
Introduction: The QT interval prolongation is an adverse effect associated with moxifloxacin.
This adverse effect can lead to potentially life-threatening arrhythmias such as Torsades de pointes.
We describe a case of severe QT interval prolongation associated with moxifloxacin which may
cause the development of Torsades de pointes. There have been no reported case of severe
corrected QT interval prolongation caused by moxifloxacin in the patient of normal heart rate.
Case presentation: In an 85-year-old Japanese woman, oral moxifloxacin 400 mg daily was
initiated for the forearm cellulitis. On the sixth day of oral moxifloxacin administration, monitor
electrocardiogram showed prolongation of the corrected QT interval to 523 ms at a rate of 40
beats/min. Electrocardiogram before moxifloxacin therapy showed the corrected QT interval to
460 ms at a rate of 72 beats/min. On the sixth day after moxifloxacin discontinuance, monitor
electrocardiogram showed the corrected QT interval to 432 ms at a rate of 70 beats/min.
Conclusion: This case suggests that electrocardiogram monitoring during moxifloxacin therapy
may be necessary in the patients even if they do not have high risk factors for QT interval
prolongation.
Introduction
Fluoroquinolones are clinically important antibiotic
drugs. Although they are generally well tolerated, with
safety profiles similar to those of other antimicrobial
agents, they may sometimes result in significant adverse
reactions [1]. The QT interval prolongation is an adverse
effect associated with fluoroquinolones. It can lead to
potentially life-threatening arrhythmias such as Torsades
de pointes (TdP). Moxifloxacin is one of the third-genera-
tion fluoroquinolones with a broad spectrum of activity,
including gram-negative, gram-positive bacteria, anaer-
obes and atypical pneumonia agents [1]. TdP associated
with moxifloxacin have been reported in the extreme
bradycardia patients who need cardiac pacemaker
implantation [2,3]. We describe a case of severe QT inter-
val prolongation associated with moxifloxacin which may
cause the development of TdP. There have been no
reported case of severe corrected QT (QTc) interval pro-
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mal heart rate.
Case presentation
An 85-year-old unconscious Japanese woman with hyper-
tension, dementia was admitted to the neurosurgery
department of our hospital. Her height was about 140 cm
and she weighed 35 kg. On admission, her head Com-
puted Tomography (CT) illustrated the fourth ventricle
hemorrhage with hydrocephalus. Admission electrocardi-
ogram (ECG) showed the QT interval to 420 ms with a
sinus rhythm at a rate of 72 beats/min. According to
Bazett's formula, the QTc interval was 460 ms. Medica-
tions she was using just before admission included slow-
release nifedipine 10 mg twice daily and famotidine 10
mg twice daily. After her admission, these medications
were stopped because of her unconsciousness. Clinical
laboratory findings at the time of admission were as fol-
lows; serum aspartate-amino transferase level was 22 IU/
L, serum alanine transaminase level was 9 IU/L, serum
total bilirubin level was 0.7 mg/dl, serum potassium level
was 4.0 mEq/L, serum urea nitrogen level was 25.9 mg/dl
and serum creatinine level was 0.6 mg/dl. Thus, renal dys-
function, hepatic dysfunction and hypokalemia were not
observed on admission. Other biochemical tests were nor-
mal. On the fifth day after admission, the ventriculo-peri-
toneal shunt was performed for hydrocephalus. As the
result, her consciousness was improved remarkably,
therefore slow-release nifedipine and famotidine were
restarted on the seventh day after admission. On the
twenty-first day after hospitalization, the right forearm
pain and swelling were developed, so oral moxifloxacin
400 mg daily was initiated for the right forearm cellulitis.
In a few days, the right forearm pain and swelling were
reduced. But on the sixth day of moxifloxacin administra-
tion, her pulse rate indicated 40 beats/min that was brady-
cardia, so monitor ECG was performed and it showed
prolongation of the QT interval to 640 ms. Using Bazett's
formula, the QTc interval was 523 ms (Figure 1). When
the severe QTc interval prolongation was developed, the
serum electrolytes, renal function and hepatic function
were normal. We assumed that the cause of severe QTc
interval prolongation was moxifloxacin, because the
severe QTc interval prolongation was observed after moxi-
floxacin therapy. Therefore, moxifloxacin was discontin-
ued. Furthermore, because the cases of QT interval
prolongation associated with famotidine have been
reported [4], famotidine was also stopped. On the sixth
day after moxifloxacin discontinuance, monitor ECG
showed the QT interval to 400 ms with a sinus rhythm at
a rate of 70 beats/min. According to Bazett's formula, the
QTc interval was 432 ms that was improved to normal
range (Figure 2).
Discussion
Moxifloxacin, like other drugs that cause an acquired long
QT syndrome, prolongs the QT intrerval by blocking the
rapid component of the delayed rectifier potassium cur-
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repolarization by blocking potassium ions flow out of
myocytes. The potency of IKr blockade and QT prolonga-
tion by moxifloxacin varies dose-dependently. Risk fac-
tors of the QT interval prolongation include female sex,
advanced age, history of long QT syndrome, organic heart
disease, bradycardia, electrolyte disturbances (particularly
hypokalemia, hypomagnesemia, hypocalcemia), renal
dysfunction, hepatic dysfunction, overdosing and co-
administration of drugs that prolong the QT interval [6].
Females generally have QTc interval about 13 ms longer
than males. The QTc interval of advanced age prolongs
approximately 6 ms compared with that of young age [7].
According to the Naranjo adverse drug reaction probabil-
ity scale, the severe QTc interval prolongation was proba-
bly related to moxifloxacin administration in this case [8].
In our patient, the QTc interval was prolonged to 523 ms,
which indicated the increase of 63 ms from her baseline
range. The QTc interval over 500 ms or increase from
baseline of more than 60 ms is a cause of TdP, according
to the Food and Drug Administration and the Committee
for Proprietary Medicinal Products [9]. Therefore, TdP
might have developed if moxifloxacin were not stopped in
our patient.
Risk factors such as organic heart failure, electrolyte
abnormalities, renal dysfunction and hepatic dysfunction
were not observed in our case. When the severe QTc inter-
val prolongation was developed, famotidine was also
stopped with moxifloxacin, because the cases of QT inter-
val prolongation associated with famotidine have been
reported [4]. Six days after moxifloxacin and famotidine
cessation, the QTc interval was improved to normal range
rather than the baseline of our patient. Her baseline QTc
interval might have been slightly prolonged by famoti-
dine. Furthermore, famotidine might have assisted in the
development of severe QTc prolongation associated with
moxifloxacin.
There have been two reported cases of TdP associated with
moxifloxacin [2,3]. These two patients had multiple risk
factors for QTc interval prolongation (female sex,
advanced age, extreme bradycardia, slight baseline QTc
interval prolongation). Particularly, they had extreme
bradycardia that needed the implantation of cardiac pace-
maker. At lower heart rates, less potassium moves out of
the cells, because the cardac repolarizations are fewer,
reducing the extracellular potassium concentration. Since
the potency of IKr inhibition is reversely related to the
extracellular potassium concentration, this reduction
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enhances the degree of IKr blockade [10]. Furthermore,
IKr inhibitor such as moxifloxacin enhances the magni-
tude of IKr inhibition additively. Therefore it seems that
the severe bradycardia assisted the development of TdP
associated with these two moxifloxacin therapy. Our
patient also had some risk factors for QTc interval prolon-
gation (female sex, advanced age, slight baseline QTc
interval prolongation, co-administration of drugs that
may prolong the QT interval), however bradycardia was
not observed at the time of admission. On the sixth day of
moxifloxacin administration, the severe QTc prolonga-
tion with bradycardia was observed for the first time.
Conclusion
We describe the severe QT interval prolongation caused
by moxifloxacin in the patient of normal heart rate. This
case suggests that ECG monitoring during moxifloxacin
therapy is necessary in the patients having some risk fac-
tors for QTc interval prolongation (female sex, advanced
age, slight baseline QTc interval prolongation, co-admin-
istration of drugs that may prolong the QT interval).
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